Business Review

 
News Articles for Business Review top ^
Harvard Business Review has ranked Seagate (NASDAQ: STX) Chairman and CEO Steve Luczo as one of the best-performing CEOs in the world.
Sign-up for Seagate’s Luczo Named as One of the “Best-Performing CEOs In the World” by Harvard Business Review investment picks
2014/9/16
57 Percent of Survey Respondents Believe IT Drives Business Growth and Innovation NEW YORK , Sept.
Sign-up for 'Decisive New Technology Adoption Leads to Competitive Advantage,' Verizon sponsored Harvard Business Review Analytic Services Survey Confirms investment picks
2014/9/17
http://media.marketwire.com/attachments/201401/215925_11Varonis_Horizontal_HEX_Whitespace.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1145200&ProfileId=051205&sourceType=1 NEW YORK, NY --
Sign-up for Harvard Business Review Highlights 'The Danger From Within' as Varonis Continues to Protect Companies From Internal Threats investment picks
2014/10/14
LAS VEGAS , Oct.
Sign-up for Harvard Business Review Names Steve Wynn Among "The Best-Performing CEOs in the World" investment picks
Allergan, Inc.’s (NYSE: AGN) (the “Company”) Chairman of the Board and Chief Executive Officer, David E.I. Pyott, has been ranked the 4 th best-performing CEO in the world by the Harvard Business Review (HBR). Mr.
Sign-up for Harvard Business Review Ranks David Pyott One of the Top 5 CEOs in the World investment picks
DENVER , Oct.
Sign-up for Harvard Business Review Recognizes DaVita HealthCare Partners investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen To Webcast 2014 Business Review Meeting On October 28 investment picks
BUNAVAIL™ (buprenorphine and naloxone) buccal film now available by prescription for the maintenance treatment of opioid dependence Positive top-line results from second Phase 3 BEMA Buprenorphine clinical trial in chronic pain; recent pre-NDA meeting confirmed NDA submission on track for year-end or early 2015 Positive interim analysis completed in Phase 3 trial of Clonidine Topical Gel for painful diabetic neuropathy; Top-line results anticipated by end of first quarter 2015 Agreement signed to develop and commercialize long-acting, injectable, microparticle formulation of buprenorphine for opioid dependence and pain to compliment current portfolio RALEIGH, N.C. , Nov.
Sign-up for BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2014 Financials investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Business Review
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Business Results  |  Next: Business School